THERAPY DOSSIER · th-8d7d09a326cc

Ryanodine (ryanodine receptor antagonist) and 2-aminoethoxydiphenyl borate (2-APB, IP3 receptor antagonist), alone and in combination

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28709993 ↗2017Reported benefit

Intracellular calcium release through IP3R or RyR contributes to secondary axonal degeneration.

MouseSpinal cord injuryHemisection / partialYFP-expressing transgenic mice (Thy1-YFP reporter line)Dissolved in artificial cerebrospinal fluid and applied by continuous bath perfusion of the ex vivo preparationApplied 1 hour after injury and perfused continuously for the remainder of the…

Model: Highly focal laser-induced spinal cord injury (LiSCI) in an ex vivo preparation, with ascending dorsal column axons severed by an 800 nm laser pulse during two-photon time-lapse imaging

Distal axonal segments retracted significantly further than proximal segments by 4 hours after laser injury. Pharmacological or genetic targeting of either the ryanodine receptor or the IP3 receptor significantly reduced proximal axonal dieback and bystander secondary degeneration at 6 hours compar…

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…